Even though very few studies are available, autopsy studies on patients with MS revealed that soluble AXL and MERTK can act as decoy receptors and block GAS6 binding, resulting in dysregulation of protective GAS6-mediated signaling, leading to prolonged lesion activity [49]. The gene discussed is MERTK; the disease is myeloid sarcoma.